# Does Idaho Medicaid Cover Wegovy or Zepbound? Obesity Drugs Are Excluded by Rule

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-11-07

Canonical page: https://glpwatchdog.org/research/idaho-medicaid-glp1-coverage

> Idaho's Medicaid rules exclude agents used to treat obesity, and the state drug list carries GLP-1s only for type 2 diabetes. Its prior authorization form covers Wegovy for heart risk and Zepbound for sleep apnea in adults without diabetes. Also: teens, a $200 weight benefit and the 28-day appeal.

## Key points

- Idaho's Medicaid rules list agents used to treat obesity among excluded drugs.
- The drug list names GLP-1s only under diabetes, and Wegovy, Zepbound and Saxenda have no entry.
- Ozempic pens, Trulicity and Victoza are preferred and need only a type 2 diabetes code on file.
- With prior authorization, adults without diabetes can get Wegovy for heart risk (BMI 27+) or Zepbound for sleep apnea (BMI 30+, AHI 15+); no MASH criteria are published.
- Idaho's Preventive Health Assistance benefit pays up to $200 a year toward a weight program for adults at a BMI of 30 and above; hearing requests are due within 28 days.

No. As of November 2026, Idaho Medicaid will not pay for Wegovy, Zepbound or any other drug used to treat obesity: its rules exclude “agents, when used for the treatment of obesity,” and its drug list names GLP-1s only for type 2 diabetes.[1][2] For diabetes the coverage is easy to reach, since Ozempic, Trulicity and Victoza are preferred and need only a diabetes diagnosis code on file.[2]

> **About this article.** This page reads Idaho’s current Medicaid benefit rules (IDAPA 16.03.26, in force since July 1, 2026), the state’s preferred drug list effective July 1, 2026 and revised September 1, 2026, and the Department of Health and Welfare’s pharmacy page, as they stood on November 7, 2026. We also read the state’s prior authorization form for GLP-1 drugs in people without diabetes. No Idaho criteria for Wegovy’s liver use could be found. To compare states, use the [state Medicaid GLP-1 checker](https://glpwatchdog.org/tools/state-medicaid-glp1-checker).

## Does Idaho Medicaid cover Wegovy for weight loss?

It does not, and the rule says so directly. Federal law lists weight-loss drugs among those a state may leave out of Medicaid.[4] Idaho’s benefit rules use that option in a short line: among excluded drugs, they list agents used to treat obesity.[1] The same section lists cough and cold remedies and drugs for sexual dysfunction.[1]

The drug list follows the rule. Its GLP-1 class appears under diabetes drugs, and a search of the whole list turns up neither an anti-obesity class nor any entry for Wegovy, Zepbound, Saxenda or Foundayo.[2] Our explainer on [why Medicaid treats Ozempic and Wegovy differently](https://glpwatchdog.org/research/does-medicaid-cover-ozempic-and-wegovy) covers the federal background.

## Does Idaho Medicaid cover Ozempic or Mounjaro for diabetes?

Yes. Ozempic pens, Trulicity and Victoza are preferred, and the only condition is a type 2 diabetes diagnosis code in the member’s Medicaid record or sent with the pharmacy claim.[2] The list says this code check works from the Medicaid record or the claim itself, so a separate request is not the usual path for these three.[2] Mounjaro, Ozempic tablets, generic liraglutide and the exenatide products are non-preferred, so they need prior authorization and, as a rule, failed trials of two preferred drugs first.[2]

*Idaho Medicaid GLP-1 status by use, from the drug list effective July 1, 2026 (revised September 1, 2026) and IDAPA 16.03.26*

| Use | Drug | Status | What it takes |
| --- | --- | --- | --- |
| Treating obesity | Wegovy, Zepbound, Saxenda | Excluded by rule | No route |
| Type 2 diabetes | Ozempic pen, Trulicity, Victoza | Preferred | Type 2 diabetes ICD-10 code on file or on the claim |
| Type 2 diabetes | Mounjaro, Ozempic tablet, liraglutide, exenatide | Non-preferred | Prior authorization; usually two preferred drugs tried first |
| Heart risk, MASH (Wegovy) | Wegovy | Not listed | No published criteria |
| Sleep apnea (Zepbound) | Zepbound | Not listed | No published criteria |

The code has to match a real diagnosis. The list ties each preferred fill to type 2 diabetes, and recording a diagnosis a person does not have would misstate the medical record.[2]

## Does Idaho Medicaid cover Wegovy for heart disease or Zepbound for sleep apnea?

Yes, with prior authorization, for adults without diabetes. Idaho’s form for these drugs in people without diabetes says Wegovy may be approved to lower heart risk after a heart attack, a stroke or symptomatic peripheral artery disease, at a BMI of 27 or more, and Zepbound may be approved for moderate to severe obstructive sleep apnea at a BMI of 30 or more, with a sleep study showing an AHI of 15 or more.[10] Both labels carry those uses.[6][7] Idaho’s exclusion is written around purpose, covering drugs “when used for the treatment of obesity,” so it does not reach them.[1]

The form asks for chart notes, a sleep study for the sleep apnea route, whether the patient uses CPAP, and the prescriber’s attestation that the patient follows a reduced-calorie diet and more physical activity and has neither type 1 nor type 2 diabetes (A1C under 6.5).[10] Approval lasts 3 months, with weight and BMI reported every 3 months to renew.[10] The form is sent by fax to (800) 327-5541; the phone line is (208) 364-1829.[10] Neither drug has a row on the drug list, so these requests go through the form rather than the list.[2] Our page on [Zepbound for sleep apnea](https://glpwatchdog.org/research/zepbound-for-sleep-apnea) covers the trials behind that approval.

## What weight help does Idaho Medicaid pay for?

Idaho pays toward weight programs rather than drugs. Its Preventive Health Assistance benefit gives adults with a BMI of 30 or more up to 200 points a year toward a weight management program, with each point worth one dollar.[1] The program must offer physical fitness, a balanced diet or health education, the primary care provider decides eligibility, and the member signs a benefit agreement to earn the points.[1] Children qualify when their BMI falls in the overweight range on the CDC calculator.[1] The same benefit also covers people who are underweight.[1]

## Can a teenager on Idaho Medicaid get Wegovy?

The obesity exclusion applies at every age in the rule, and the drug list has no teen route.[1][2] Wegovy is approved for obesity from age 12.[6] Federal child-health rules, known as EPSDT, require Medicaid to provide necessary treatment for members under 21 even when the state plan does not cover it.[5] No Idaho document applying that rule to GLP-1s could be found, so a family that wants to try would ask for review on that basis with full records. Our review of [GLP-1 drugs in teenagers](https://glpwatchdog.org/research/glp1-drugs-in-teenagers) covers the evidence.

## How do prior authorization and appeals work in Idaho?

Prime Therapeutics runs pharmacy benefits for the state.[3] Prescribers fax prior authorization requests to 800-327-5541 and can check status at 800-922-3987; members have their own line at 888-773-9466.[3] The rules commit the department to answer a drug prior authorization request within 24 hours.[1] The drug list adds that samples, patient assistance and self-pay are not counted when a request is evaluated, so months paid in cash do not count as a trial.[2]

The appeal window is short. After a denial, the department issues a notice of decision, and the member has 28 days from the date of the denial to request a fair hearing.[1] An appeal has little to argue when the request is for weight loss alone, because the rule excludes that use.[1] Our walkthrough of [prior authorization and appeals](https://glpwatchdog.org/research/glp1-prior-authorization-and-appeals) covers what to include, and the [Idaho state page](https://glpwatchdog.org/states/idaho) summarizes the Medicaid facts. State employees have a separate plan with its own rules.

## What can you do if Idaho Medicaid won’t pay?

Cash is the main option. Lilly’s copay card terms exclude anyone enrolled in Medicaid, so the card cannot lower the price.[8] In the figures we track, Novo Nordisk sells most Wegovy pen doses for $349 a month to self-pay patients, and Lilly’s Zepbound runs from $299 at the starting dose to $449 at higher doses refilled on time.[8][9] Read each program’s terms on government coverage first, and compare them in our list of the [cheapest ways to pay without insurance](https://glpwatchdog.org/research/cheapest-glp1-without-insurance).

## Frequently asked questions

### Does Idaho Medicaid cover Wegovy?

Not for weight loss. As of November 2026, Idaho's Medicaid rules exclude drugs used to treat obesity, and Wegovy does not appear on the state drug list. Idaho's form for patients without diabetes does allow Wegovy, with prior authorization, to lower heart risk in adults with a past heart attack, stroke or symptomatic artery disease and a BMI of 27 or more.

### Does Idaho Medicaid cover Ozempic?

Yes, for type 2 diabetes. The Ozempic pen is a preferred drug, and the only condition is a type 2 diabetes diagnosis code in the member's Medicaid record or on the pharmacy claim. Ozempic tablets are non-preferred and need prior authorization.

### Does Idaho Medicaid cover Zepbound for sleep apnea?

Yes, with prior authorization, for adults without diabetes. Idaho's form allows Zepbound for moderate to severe obstructive sleep apnea at a BMI of 30 or more, with a sleep study showing an AHI of 15 or more. Approvals last 3 months, with weight and BMI reported to renew.

### Does Idaho Medicaid pay for weight loss programs?

Yes. Idaho's Preventive Health Assistance benefit gives adults with a BMI of 30 or more up to $200 a year toward a weight management program offering fitness, diet or health education. The primary care provider decides eligibility, and the member signs a benefit agreement.

### How long do I have to request a fair hearing in Idaho?

Idaho's Medicaid rules give a member 28 days from the date of a denial to request a fair hearing on the decision. The department sends a notice of decision, so count from the denial date it shows.

## References

1. Idaho Department of Health and Welfare, Division of Medicaid IDAPA 16.03.26: Medicaid Plan Benefits. Idaho Office of the Administrative Rules Coordinator. 2026. https://adminrules.idaho.gov/rules/current/16/160326.pdf
2. Idaho Department of Health and Welfare Idaho Medicaid Preferred Drug List with Prior Authorization Criteria, effective July 1, 2026, last revised September 1, 2026. publicdocuments.dhw.idaho.gov. 2026. https://publicdocuments.dhw.idaho.gov/WebLink/ElectronicFile.aspx?docid=15075&dbid=0&repo=PUBLIC-DOCUMENTS
3. Idaho Department of Health and Welfare Idaho Medicaid Pharmacy Program. healthandwelfare.idaho.gov. 2026. https://healthandwelfare.idaho.gov/providers/pharmacy-providers/idaho-medicaid-pharmacy-program
4. United States Code 42 U.S.C. §1396r-8: Payment for covered outpatient drugs (Social Security Act §1927). Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/uscode/text/42/1396r-8
5. United States Code 42 U.S.C. §1396d: Definitions, including early and periodic screening, diagnostic, and treatment services (subsection r). Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/uscode/text/42/1396d
6. Novo Nordisk WEGOVY (semaglutide) injection and tablets: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
7. Eli Lilly and Company ZEPBOUND (tirzepatide) injection: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
8. Eli Lilly and Company Zepbound savings and self-pay options, with card terms. zepbound.lilly.com. 2026. https://zepbound.lilly.com/savings
9. Novo Nordisk Wegovy savings offer. novocare.com. 2026. https://www.novocare.com/obesity/products/wegovy/savings-offer.html
10. Idaho Department of Health and Welfare, Division of Medicaid Prior Authorization Form: GIP and GLP-1 Receptor Agonists for Non-Diabetic Patients with Comorbidities (new January 16, 2025). publicdocuments.dhw.idaho.gov. 2025. https://publicdocuments.dhw.idaho.gov/WebLink/DocView.aspx?id=32324&dbid=0&repo=PUBLIC-DOCUMENTS

---

Cite as: GLP Watchdog, Nora Bissett, "Does Idaho Medicaid Cover Wegovy or Zepbound? Obesity Drugs Are Excluded by Rule", published 2026-11-07. https://glpwatchdog.org/research/idaho-medicaid-glp1-coverage

Canonical HTML page: https://glpwatchdog.org/research/idaho-medicaid-glp1-coverage

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.